This study compares four treatments to see which one causes the most weight loss, fat loss, loss of abdominal fat and improvement in blood tests like cholesterol. The four treatments are: Placebo, Ephedrine plus caffeine, Pioglitazone, Combined pioglitazone and ephedrine plus caffeine
The sympathetic nervous system, via the intracellular messenger cAMP and MAPK activation, and thiazolidinediones via PPARγ control lipid metabolism have been implicated in body weight regulation. The present study was undertaken to determine whether the simultaneous activation of these two signaling systems might synergize to exert beneficial effects on the expression of key genes involved in lipid metabolism and mitochondrial biogenesis in subcutaneous fat in healthy, non-diabetic subjects. Fifty seven non-diabetic women and men were randomized into four groups: 1) placebo/placebo (PP); 2) ephedrine plus caffeine/placebo (ECP); 3) placebo/pioglitazone (PPio); 4) ephedrine plus caffeine/pioglitazone (ECPio). Adipose tissue samples were obtained after 12 weeks of treatment to determine gene expression by real time RT-PCR.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
96
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States
Percent fat after 16 weeks treatment using a Hologic QDR 4500 DEXA.
UCP-1 gene expression by quantitative RT-PCR
fat mass, lean mass
visceral adiposity by multi-slice CT scanning
resting metabolic rate and thermic effect of a single dose of ephedrine and caffeine
adipose tissue gene expression profiling using oligonucleotide array
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.